By Connor Hart
Super Micro Computer cut its sales outlook for fiscal 2025, citing short-term impacts of heightened economic uncertainty and tariffs that prompted some customers to delay orders. The server maker now expects sales of $21.8 billion to $22.6 billion for its fiscal-year ending June 30, down from a prior outlook of $23.5 million to $25 billion. The cut came as the company reported third-quarter results in-line with a preliminary report last week that was well below previously-issued guidance. Shares fall 5.6%, to $31.07, in after-hours trading.
Electronic Arts logged higher profit and revenue in its fiscal fourth quarter, while guiding for the upcoming launch of a new game in its Battlefield franchise to drive results in the current fiscal year. The videogame developer posted earnings of 98 cents a share on revenue of $1.9 billion, compared with Wall Street estimates for a profit of $1.05 a share on revenue of $1.56 billion. For its fiscal 2026, EA forecast per-share earnings of $3.09 to $3.79 on revenue of $7.1 billion to $7.5 billion. Shares climb 5.4%, to $162.88, in post-market trading.
WW International filed for bankruptcy to adjust to the increasing use of drugs like Ozempic for weight loss. The company, formerly known as WeightWatchers, has been offering drugs as a complement to its legacy business model of providing food consumption and exercise plans, though its clinical business hasn't grown fast enough to offset the decline in subscriptions to its core programs. CEO Tara Comonte said the company's debt load has been a burden, and that she is hopeful that deleveraging will help free up cash flow so it can innovate and compete. Shares tumble 51%, to 39 cents, in after-hours trading.
Sarepta Therapeutics cut its full-year outlook, citing significant pressures hurting the broader biotech market. The company said it now expects total net product revenue of $2.3 billion to $2.6 billion for the year, down from a prior forecast of $2.9 billion to $3.1 billion. The cut came as Sarepta swung to a loss in the first quarter, hurt by higher research and development expenses, though revenue jumped 80% and beat estimates. Shares fall 21%, to $37.13, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
May 06, 2025 19:27 ET (23:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.